0001209191-19-002822.txt : 20190108
0001209191-19-002822.hdr.sgml : 20190108
20190108165912
ACCESSION NUMBER: 0001209191-19-002822
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190104
FILED AS OF DATE: 20190108
DATE AS OF CHANGE: 20190108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hahn Mark W
CENTRAL INDEX KEY: 0001408502
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38135
FILM NUMBER: 19516552
MAIL ADDRESS:
STREET 1: 6340 QUADRANGLE DRIVE
STREET 2: SUITE 100
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001685071
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813858961
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
BUSINESS PHONE: 919-806-4487
MAIL ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
FORMER COMPANY:
FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20160919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-04
0
0001685071
Dova Pharmaceuticals Inc.
DOVA
0001408502
Hahn Mark W
C/O DOVA PHARMACEUTICALS, INC.
240 LEIGH FARM ROAD, SUITE 245
DURHAM
NC
27707
0
1
0
0
Chief Financial Officer
Common Stock
2019-01-04
4
A
0
8844
A
11344
D
Employee Stock Option (right to buy)
8.82
2019-01-04
4
A
0
250000
0.00
A
2029-01-03
Common Stock
250000
250000
D
Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019.
Each RSU represents a contingent right to receive one share of Issuer common stock.
25% of the total shares subject to the option shall vest on December 31, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.
/s/ Mark Ballantyne, Attorney-in-Fact
2019-01-08